CD163: A specific immunohistochemical marker for acute myeloid leukemia with monocytic differentiation

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 5, 2008, Pages 417-421

  Garcia, Christine ^a   Gardner, David ^a   Reichard, Kaaren K ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Acute leukemia; CD163; CD68; Monocytic

Indexed keywords

BIOLOGICAL MARKER; CD163 ANTIGEN; CD68 ANTIGEN; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOCHEMISTRY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; CHEMISTRY; COMPARATIVE STUDY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; PATHOLOGY;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL DIFFERENTIATION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MONOCYTES; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 55949091156     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31815db477     Document Type: Article

References (23)

1. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099-2107. (Pubitemid 44665642)
2. Brunning RD, Bennett J, Matutes E, et al. Acute myeloid leukemias. In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumors: Tumors of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2001:77-105.
3. Arber DA, Stein AS, Carter NH, et al. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol. 2003;119:672-680.
4. Cox-Froncillo MC, Genuardi M, Bajer J, et al. First report of t(8;21)(q22;q22) in a case of de novo acute monoblastic leukemia. Cancer Genet Cytogenet. 1995;79:82-85.
5. Molero MT, Gomez Casares MT, Valencia JM, et al. Detection of a t(8;21)(q22;q22) in a case of M5 acute monoblastic leukemia. Cancer Genet Cytogenet. 1998;100:176-178. (Pubitemid 128766365)
6. Le Beau MM, Larson RA, Bitter MA, et al. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med. 1983;309:630-636.
7. Secker-Walker LM, Moorman AV, Bain BJ, et al. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop. Leukemia. 1998;12:840-844.
8. Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia. 1993;7:1975-1986.
9. Warnke RA, Pulford KA, Pallesen G, et al. Diagnosis of myelomonocytic and macrophage neoplasms in routinely processed tissue biopsies with monoclonal antibody KP1. Am J Pathol. 1989; 135:1089-1095. (Pubitemid 20026528)
10. Facchetti F, Bertalot G, Grigolato PG. KP1 (CD 68) staining of malignant melanomas. Histopathology. 1991;19:141-145.
11. Gloghini A, Rizzo A, Zanette I, et al. KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas. Am J Clin Pathol. 1995;103:425-431.
12. Carbone A, Gloghini A, Volpe R, et al. KP1 (CD68)-positive large cell lymphomas: a histopathologic and immunophenotypic characterization of 12 cases. Hum Pathol. 1993;24:886-896. (Pubitemid 23238968)
13. Arber DA, Jenkins KA. Paraffin section immunophenotyping of acute leukemias in bone marrow specimens. Am J Clin Pathol. 1996;106:462-468. (Pubitemid 26332995)
14. Nguyen TT, Schwartz EJ, West RB, et al. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/ macrophage lineage. Am J Surg Pathol. 2005;29:617-624.
15. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004;122:794-801.
16. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198-201.
17. Schaer DJ, Schaer CA, Buehler PW, et al. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood. 2006;107:373-380.
18. Bachli EB, Schaer DJ, Walter RB, et al. Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage. J Leukoc Biol. 2006;79:312-318.
19. Vos JA, Abbondanzo SL, Barekman CL, et al. Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163. Mod Pathol. 2005;18:693-704.
20. Radzun HJ, Kreipe H, Bodewadt S, et al. Ki-M8 monoclonal antibody reactive with an intracytoplasmic antigen of monocyte/ macrophage lineage. Blood. 1987;69:1320-1327. (Pubitemid 17085286)
21. Backe E, Schwarting R, Gerdes J, et al. Ber-MAC3: new monoclonal antibody that defines human monocyte/macrophage differentiation antigen. J Clin Pathol. 1991;44:936-945.
22. Walter RB, Bachli EB, Schaer DJ, et al. Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in acute myeloid leukemia. Blood. 2003;101:3755-3756.
23. Brunning RD, McKenna RW. Acute myeloblastic leukemia with maturation (AML-M2). In: Brunning RD, McKenna RW, eds. Tumors of the Bone Marrow. Atlas of Tumor Pathology. 3rd series, fascicle 9. Washington, DC: Armed Forces Institute of Pathology; 1994:37-43.